Abstract
AbstractSmall interfering ribonucleic acid (siRNA) molecules are used for gene silencing by activating a degradation pathway for transcribed mRNA molecules after they are transcribed. By complementing a highly specific sequence of the mRNA, the siRNA prevent translation of the mRNA into the targeted protein. They have long been the subject of translational research as treatments for various diseases, but only recently has the expectation come closer to realization. This talk will discuss the development of improved siRNA therapies and review their use in the laboratory and some recent and currently active clinical trials.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
